Literature DB >> 2687401

Complexes of soluble HLA antigens and anti-HLA autoantibodies in human sera: possible role in maintenance of self-tolerance.

D W King1, E Reed, N Suciu-Foca.   

Abstract

The MHC plays an essential role in regulating the process of self-nonself discrimination. T cells recognize nonself antigens only in the context of self-MHC gene products. It is not clear, however, whether B cells are also endowed with immune receptors for self-MHC antigens. We have explored the existence of antibodies against self-MHC antigens (HLA) in the human by analyzing the specificity of anti-HLA antibodies developed by a population of 727 dialysis patients who had been monitored monthly over a period of 3-78 months. Anti-HLA autoantibodies were identified by serum screening in 119 patients. Twenty-five of these 119 patients had not been exposed to alloantigens before, indicating that the production of anti-HLA autoantibodies is not necessarily stimulated by allogeneic HLA antigens. Cross-matching of sera with autologous lymphocytes, confirmed the autoreactive nature of these anti-HLA antibodies which were of IgM or of IgG isotype in approximately equal numbers of patients. The fine specificities of anti-HLA autoantibodies was ascertained in studies which showed that antibodies can be adsorbed, and the eluted, from the membranes of target cells carrying then relevant HLA antigen. Since the antibodies characterized in our studies may be functionally active in vivo we examined the possibility that their level is controlled by anti-idiotypic antibodies or by soluble HLA antigens. We found that the titer of anti-HLA autoantibodies increased significantly if soluble HLA antigens were depleted from the serum. Our data suggest that circulating HLA antigens form immune complexes with anti-HLA autoantibodies and contribute to the maintenance of self-tolerance by inhibiting antibody binding to membrane HLA antigens. The finding that the immune repertoire includes B cells with receptors for self-MHC opens new perspectives for the study of network perturbations in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2687401     DOI: 10.1007/bf02935510

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  21 in total

1.  Natural autoreactive H-2-specific serum antibodies in a group of BALB/cBy (H-2d) mice.

Authors:  R Cerný-Provaznik; T Kloosterman; D Verkerk; T M Vroom; P Iványi
Journal:  Tissue Antigens       Date:  1986-02

2.  Escape from sensitization to HL-A antibodies.

Authors:  T Miyajima; A A Hirata; P I Terasaki
Journal:  Tissue Antigens       Date:  1972

3.  Natural HLA antibodies.

Authors:  M M Tongio; A Falkenrodt; Y Mitsuishi; A Urlacher; J P Bergerat; M L North; S Mayer
Journal:  Tissue Antigens       Date:  1985-11

Review 4.  Human anti-HLA monoclonal antibodies: production, characterization, and application.

Authors:  M P Pistillo; O Mazzoleni; N Tanigaki; U Hammerling; A Longo; G Frumento; G B Ferrara
Journal:  Hum Immunol       Date:  1988-04       Impact factor: 2.850

5.  Antibodies in the sera of patients with systemic lupus erythematosus that block the binding of monoclonal anti-Ia to Ia-positive targets also inhibit the autologous mixed lymphocyte response.

Authors:  K Okudaira; R P Searles; J S Goodwin; R C Williams
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

Review 6.  Studies on natural antibodies and autoantibodies.

Authors:  S Avrameas; G Dighiero; P Lymberi; B Guilbert
Journal:  Ann Immunol (Paris)       Date:  1983 Jul-Aug

7.  Effect of antiidiotypic antibodies to HLA on graft survival in renal-allograft recipients.

Authors:  E Reed; M Hardy; A Benvenisty; C Lattes; J Brensilver; R McCabe; K Reemstma; D W King; N Suciu-Foca
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

8.  Successful transplantation with a positive T and B cell crossmatch due to autoreactive antibodies.

Authors:  A Ting; P J Morris
Journal:  Tissue Antigens       Date:  1983-03

9.  Anti-clonotypic autoantibodies in pregnancy.

Authors:  V R Bonagura; A Ma; J McDowell; A Lewison; D W King; N Suciu-Foca
Journal:  Cell Immunol       Date:  1987-09       Impact factor: 4.868

10.  Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome.

Authors:  H Golding; F A Robey; F T Gates; W Linder; P R Beining; T Hoffman; B Golding
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  5 in total

1.  Identification, characterization, and quantitation of soluble HLA antigens in the circulation and peritoneal dialysate of renal patients.

Authors:  F B Gelder; J C McDonald; M D Landreneau; R M McMillan; D F Aultman
Journal:  Ann Surg       Date:  1991-06       Impact factor: 12.969

Review 2.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

3.  Immunomodulation of kidney and heart transplants by anti-idiotypic antibodies.

Authors:  M A Hardy; N Suciu-Foca; E Reed; A I Benvenisty; C Smith; E Rose; K Reemtsma
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

4.  Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients.

Authors:  E Reed; E Ho; D J Cohen; W Ramey; C Marboe; V D'Agati; E A Rose; M Hardy; N Suciu-Foca
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Serum and urine soluble HLA class I antigen concentrations are increased in patients with hemorrhagic fever with renal syndrome.

Authors:  C W Park; S N Yun; C W Yang; T G Kim; H Han; E J Choi; Y S Chang; B K Bang
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.